Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.49 USD | +8.42% | +7.85% | +141.79% |
Financials (USD)
Sales 2024 * | 96.88M | Sales 2025 * | 117M | Capitalization | 723M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -22M | EV / Sales 2024 * | 6.35 x |
Net cash position 2024 * | 109M | Net cash position 2025 * | 130M | EV / Sales 2025 * | 5.1 x |
P/E ratio 2024 * |
-32
x | P/E ratio 2025 * |
-38.3
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.46% |
Latest transcript on Y-mAbs Therapeutics, Inc.
1 day | +8.42% | ||
1 week | +7.85% | ||
Current month | +8.42% | ||
1 month | +1.85% | ||
3 months | +23.15% | ||
6 months | +194.46% | ||
Current year | +141.79% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Gad
FOU | Founder | 54 | 15-03-31 |
Michael Rossi
CEO | Chief Executive Officer | 53 | Nov. 05 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Gill
BRD | Director/Board Member | 69 | 17-11-30 |
Director/Board Member | 54 | 15-08-31 | |
James Healy
CHM | Chairman | 58 | 17-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 509 M€ | -.--% | ||
0.01% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 16.49 | +8.42% | 365,232 |
24-04-30 | 15.21 | -1.87% | 214,271 |
24-04-29 | 15.5 | +5.37% | 158,043 |
24-04-26 | 14.71 | -0.88% | 189,796 |
24-04-25 | 14.84 | -2.94% | 365,385 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+141.79% | 667M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- YMAB Stock